Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02342444 · ClinicalTrials.gov registry record · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
A Phase 4 study of Surgery and Trauma, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 606
- Enrollment target
- 1
- Study location
NCT02342444: Recruiting Phase 4 study of Surgery and Trauma, sponsored by Oregon Health and Science University.
NCT02342444 is a Phase 4 study of Surgery and Trauma that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 606 participants, below the 52,847-participant average among 120 other Surgery trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02342444, a Phase 4 study of Surgery and Trauma, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 606 participants
- Enrollment target
- 1
- Study location
Study Summary
The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox) is given to patients who are at a higher risk of developing clots in their legs or lungs. There are two standard doses of enoxaparin that are recommended by the drug companies. These two doses have never been directly compared in trauma, general, and vascular surgery patients. The purposes of this study are: 1. to compare the development of blood clots in patients receiving 30mg twice daily of enoxaparin compared to patients receiving 40mg once daily of enoxaparin. 2. to determine if there is higher risk of bleeding complications in patients receiving 30mg twice daily of enoxaparin compared to patients receiving 40mg once daily. Patients enrolled into the study will be randomized to receive enoxaparin, 30mg twice daily or enoxaparin, 40mg once daily. Patients will then be monitored for signs and symptoms of blood clots. At the time of discharge (or before, if medically indicated), an ultrasound test will be performed to look for blood clots in the patient's legs. The investigators will compare incidence of blood clots formed between the 2 groups of patients to determine if one dose of enoxaparin relates to a lower rate of blood clots in critically ill patients. The investigators will also compare the incidence of bleeding complications between the 2 groups.
Conditions Studied
Interventions
- DRUG Enoxaparin Sodium Injection 30 mg BID
- DRUG Enoxaparin Sodium Injection 40 mg QD
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 606 participants |
| Start Date | 2014-02 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 4 |
What NCT02342444 shows while recruiting
NCT02342444 is an interventional study that assigns participants to a tested intervention. The registered 606 participants enrollment target is mid-sized for trials with a published cap, below the 52,847-participant average among 120 other Surgery trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Surgery appearing as the primary indexed condition, and to 2 interventions - of which Enoxaparin Sodium Injection 30 mg BID is the first listed.
NCT02342444 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT02342444 about?
NCT02342444 is a clinical study titled "Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)". The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox) is given to patients who are at a higher risk of developing clots in their legs or lungs. There are two standard doses of enoxaparin that are recommended by the drug companies. T...
What is the current status of trial NCT02342444?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 606 participants. The study started on 2014-02. Estimated completion is 2025-03-31.
What conditions does trial NCT02342444 study?
This clinical trial studies the following conditions: Surgery, Trauma, Deep Vein Thrombosis (DVT), Thromboembolic Events.
What interventions are being tested in trial NCT02342444?
The interventions under investigation include: Enoxaparin Sodium Injection 30 mg BID (DRUG), Enoxaparin Sodium Injection 40 mg QD (DRUG).
Who is sponsoring clinical trial NCT02342444?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02342444 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgery
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02342444's enrollment target sits among peer trials
606 19th of 120 higher than 102 of 120 other Surgery trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Surgery trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparing Analgesic Regimen Effectiveness and Safety for Surgery (CARES) Trial
RECRUITING · Phase 4
-
Continuous Versus Single Injection Adductor Canal Blocks for Outpatient Total Knee Arthroplasty
RECRUITING · Phase 4
-
Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
RECRUITING · Phase 4
-
Transversus Abdominis Plane Block Compared to Local Anesthetic Wound Infiltration in Gynecologic Oncology Surgery
RECRUITING · Phase 4
-
Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial
RECRUITING · Phase 4
-
Multimodal Analgesia Effect on Post Surgical Patient
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02064673 · 608 participants · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
- NCT06091202 · 608 participants · Phase 3
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
- NCT06098144 · 608 participants · Phase 4
Smoking Cessation Program in the Construction Sector
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia